Recommendations Developed for Psoriatic Arthritis Treatment
Guideline includes use of treat-to-target strategy for all adult patients with active PsA
Many Americans Unaware of Promise of Personalized Medicine
41 percent are not at all familiar with personalized medicine; only 5 percent say they are very familiar
SABCS: Delaying Chemo Lowers Survival in Triple-Neg Breast CA
Findings show delaying chemo over 30 days postsurgery lowers triple-negative breast cancer survival
Infections Linked to Increased Later Risk for Mental Disorders
Subsequent risk increased with infections requiring hospitalization, treatment with anti-infective agents
FDA Warns of Rare Stroke Risk With Multiple Sclerosis Drug
Alemtuzumab label will be updated to include the risk for stroke and arterial dissection
SABCS: T-DM1 Cuts Recurrent Invasive HER2+ Breast CA Risk
Risk reduced with trastuzumab emtansine in those with residual invasive dz at sx after neoadjuvant chemo
ASH: A+CHP Bests CHOP for Peripheral T-Cell Lymphoma
Median progression-free survival improved with A+CHP vs CHOP; similar incidence of adverse events
ASH: Rivaroxaban Prevents Blood Clots in At-Risk Cancer Patients
Risk for patients in rivaroxaban group reduced during the on-treatment period
Urate Elevation in Potential Tx for Parkinson’s Not Tied to HTN
Phase II clinical trial results, mouse model study show no link between serum urate, changes in BP
Mean Cumulative Lifetime Prevalence of Eczema 9.9 Percent
Highest rates of active disease seen for children aged 0 to 17 years and older adults aged 75 to 99
